<p>Ovid Therapeutics Chairman Jeremy Levin talks with Scrip about how the US should view its biotech sector as a strategic national asset and urges the venture capital sector to place more emphasis on supporting early and innovative science.

</p>

Ovid Therapeutics Chairman Jeremy Levin talks with Scrip about how the US should view its biotech sector as a strategic national asset and urges the venture capital sector to place more emphasis on supporting early and innovative science.

Scrip Deals Podcast: An Interview With Jeremy Levin

Scrip delivers expert-driven audio insight on biopharma — from R&D, commercial strategy and deal activity to coverage of major industry events. Every Monday, Ian Haydock presents Quick Listen: Five Must-Know Things, a weekly roundup of top industry stories. Joseph Haas hosts a quarterly deep-dive into dealmaking with guests from leading companies, law firms and investment firms. Visit https://insights.citeline.com/scrip to sign up. For any podcast feedback or queries, you can now reach us at podcasts@norstella.com.

Business

Scrip delivers expert-driven audio insight on biopharma — from R&amp;D, commercial strategy and deal activity to coverage of major industry events. Every Monday, Ian Haydock presents Quick Listen: Five Must-Know Things, a weekly roundup of top industry stories. Joseph Haas hosts a quarterly deep-dive into dealmaking with guests from leading companies, law firms and investment firms. Visit https://insights.citeline.com/scrip to sign up. For any podcast feedback or queries, you can now reach us at podcasts@norstella.com.

Share Scrip Deals Podcast: An Interview With Jeremy Levin

Sign up to save your podcasts

Scrip Deals Podcast: An Interview With Jeremy Levin

Scrip Deals Podcast: An Interview With Jeremy Levin